Cellafa Bioscience builds robot-and-AI cell manufacturing platform

Cellafa Bioscience (セラファ・バイオサイエンス), a company set up by YASKAWA Electric and Astellas Pharma, is developing and providing a manufacturing technology platform for regenerative medicine products that uses general-purpose humanoid robots and AI, the business daily Nikkan Kogyo Shimbun reported. The company began operating in October 2025 and aims to lower the cost of manufacturing regenerative medicine products.

Cell manufacturing has long resisted automation. Antibody production was automated early by connecting bioreactors and chromatography with piping, and steps that only move liquid are easy to hand to equipment. Cell therapy is different in three ways. Batches are small and numerous: autologous therapy is one patient per batch, so there are no economies of scale. Processes branch, with judgments such as when to passage cells or how far to dilute them depending on how they grow. Containers are not standardized either. Flasks, bags and plates are mixed, so a machine built for one step cannot be reused for others. Closed, automated devices exist for single steps, but people still run the full sequence, and operator skill holds up quality.

A general-purpose humanoid robot that reproduces human work can use existing tools and procedures, so the process does not have to be rebuilt around a machine. When the process changes, the robot can be retaught instead of replaced. The trade-off is that it works within roughly human speed and precision, so it cannot deliver the order-of-magnitude speedups of a dedicated machine. The gains are reproducibility and operating hours: the same motions in the same order, without fatigue or individual differences, and without staff standing by.

Robots also leave a record of what they did, when, in what order and for how long. Manual work does not; a batch record notes that a step was done, not how it was done. Those records can support deviation investigations, show which operations actually affect results, and let a site transfer motion definitions rather than procedures alone.

Cell therapy costs are driven more by labor and cleanroom time than by materials, and failed batches hurt because patient starting material cannot be remade. Automation helps through lower failure rates and parallel runs in the same facility. It does not remove equipment qualification, computerized system validation or process validation, and when AI takes part in decisions, the basis for calling those decisions valid has to be worked out. A company formed by an equipment maker and a drug maker fits that task of settling machine performance and GMP use together.